This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Dynepo

Shire Pharmaceuticals Group PLC

Drug Names(s): Dynepo, Epoietin Delta

Description: The active ingredient of Dynepo, Epoietin Delta, is human erythropoietin prepared from cultured human cell lines.

Deal Structure: TKT entered into an agreement with Aventis in May 1994 focused on the development of Dynepo. Under the agreement, TKT has the potential to receive up to $38.0 million, consisting of license fees, equity investments, milestone payments, and research funding, of which TKT had received $20.0 million as of December 31, 2002. The remaining payments are contingent upon the achievement of regulatory and commercial milestones. TKT also is entitled to a low double-digit royalty on net sales of Dynepo by Aventis.

In March of 2004, Transkaryotic Therapies announced that Aventis Pharmaceuticals returned rights to Dynepo to TKT for all indications in Europe and all other territories outside the United States.

Under the revised agreement, TKT will pay Aventis a scaled royalty on Dynepo sales. Aventis will retain rights to commercialize Dynepo in the United States under essentially the same terms as the original agreement and has obtained an option on certain TKT gene therapy technology for...See full deal structure in Biomedtracker

Partners: Sanofi Lonza Group Ltd.


Dynepo News

Pink Sheet Aventis/TKT Dynepo


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug